FANCA safeguards interphase and mitosis during hematopoiesis in vivo

• Published in: Experimental hematology Vol. 43; no. 12; pp. 1031 - 1046.e12
• Main Authors: Abdul-Sater, Zahi, Cerabona, Donna, Potchanant, Elizabeth Sierra, Sun, Zejin, Enzor, Rikki, He, Ying, Robertson, Kent, Goebel, W. Scott, Nalepa, Grzegorz
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.12.2015
• Subjects: Advanced Basic Science; Animals; Fanconi Anemia - genetics; Fanconi Anemia - metabolism; Fanconi Anemia - pathology; Fanconi Anemia - therapy; Fanconi Anemia Complementation Group A Protein - genetics; Fanconi Anemia Complementation Group A Protein - metabolism; Female; Hematology, Oncology and Palliative Medicine; Hematopoiesis; Humans; Interphase; Male; Mice; Mice, Knockout; Mitosis; Spindle Apparatus - genetics; Spindle Apparatus - metabolism; Spindle Apparatus - pathology
• ISSN: 0301-472X; 1873-2399
• DOI: 10.1016/j.exphem.2015.08.013

The Fanconi anemia (FA/BRCA) signaling network controls multiple genome-housekeeping checkpoints, from interphase DNA repair to mitosis. The in vivo role of abnormal cell division in FA remains unknown. Here, we quantified the origins of genomic instability in FA patients and mice in vivo and ex vivo. We found that both mitotic errors and interphase DNA damage significantly contribute to genomic instability during FA-deficient hematopoiesis and in nonhematopoietic human and murine FA primary cells. Super-resolution microscopy coupled with functional assays revealed that FANCA shuttles to the pericentriolar material to regulate spindle assembly at mitotic entry. Loss of FA signaling rendered cells hypersensitive to spindle chemotherapeutics and allowed escape from the chemotherapy-induced spindle assembly checkpoint. In support of these findings, direct comparison of DNA crosslinking and anti-mitotic chemotherapeutics in primary FANCA− / − cells revealed genomic instability originating through divergent cell cycle checkpoint aberrations. Our data indicate that FA/BRCA signaling functions as an in vivo gatekeeper of genomic integrity throughout interphase and mitosis, which may have implications for future targeted therapies in FA and FA-deficient cancers.